CDT Equity advances AZD5904 to PCT stage and seeks pharma partner
CDT Equity has moved AZD5904, its myeloperoxidase (MPO) inhibitor originally in-licensed from AstraZeneca, into the Patent Cooperation Treaty (PCT) phase, broadening the asset's international intellectual property coverage. The NASDAQ-listed biopharmaceutical company is simultaneously opening formal discussions with potential pharmaceutical partners to take AZD5904 into later-stage clinical development.
The company holds both a composition of matter patent and a method of use patent for AZD5904 in idiopathic male infertility, and says the PCT filing now enables it to pursue protection across a wider set of jurisdictions. CDT has also flagged oncology-associated infertility as a secondary indication of commercial interest, though the release provides no data on that signal beyond describing it as "promising."
The asset and its clinical history
AZD5904's most substantive selling point is its existing human safety record. A total of 181 subjects were dosed across five Phase 1 studies, with the company reporting no overtly drug-related adverse events. That safety dataset was generated under AstraZeneca before CDT acquired the licence, and it represents the entirety of the clinical programme to date — there are no efficacy data from a controlled trial in CDT's target indication of male infertility.
Dr Joanne Holland, Chief Scientific Officer at CDT, said the asset combines "human safety data, pre-clinical mechanistic validation, and a growing intellectual property position," adding that the PCT transition allows the company to "take a global view on development and partnering."
The absence of Phase 2 data is the key risk any prospective partner will need to weigh. CDT is positioning AZD5904 as "clinically de-risked" on the strength of Phase 1 tolerability, but the path to regulatory approval in either male infertility or oncology-associated infertility remains long and largely uncharted from a clinical evidence standpoint.
Market context and competitive landscape
Idiopathic male infertility is a medically and commercially under-served area. No pharmacological treatment is currently approved by the FDA or EMA for the condition, which affects an estimated 30–40% of infertile couples where a male factor is identified. That regulatory whitespace is both an opportunity and a risk: the clinical development pathway lacks the well-trodden precedents available in larger therapeutic areas, and endpoints for a pivotal trial would likely require careful alignment with regulators.
MPO inhibition as a therapeutic strategy has attracted interest across several inflammatory and oxidative-stress-linked indications, including cardiovascular disease and neurodegeneration, though no MPO inhibitor has yet reached late-stage approval in any indication. CDT's focus on male infertility is a relatively niche application of the mechanism, and the competitive field in that specific indication is thin — which cuts both ways for a company seeking a large pharma partner.
CDT, formerly known as Conduit Pharmaceuticals, describes itself as a platform company using artificial intelligence and solid-form chemistry to reposition and advance assets. AZD5904 appears to be its lead publicly disclosed programme. The company has not disclosed a timeline for completing a partnering deal, nor the financial terms it is seeking through licensing arrangements.
Investors will be watching for a named development partner and, beyond that, for any indication of when a clinical-stage study in the infertility indication might be initiated — the two milestones that would most materially de-risk the asset and validate CDT's out-licensing thesis.